We are live on ! Find out more
CM

Caption Management Portfolio holdings

AUM $17.1B
1-Year Est. Return 70.99%
This Fund
S&P 500
This Quarter Est. Return
+5.52%
1 Year Est. Return
+70.99%
3 Year Est. Return
+176.06%
5 Year Est. Return
+263.89%
10 Year Est. Return
AUM
$5.65B
AUM Growth
+$471M
Cap. Flow
+$283M
Cap. Flow %
5.01%
Top 10 Hldgs %
17.56%
Holding
1,507
New
476
Increased
192
Reduced
202
Closed
448

Top Sells

Rank Stock Value
1
KWEB icon
KraneShares CSI China Internet ETF
KWEB
+$16.7M
2
SABR icon
Sabre
SABR
+$12.5M
3
UBS icon
UBS Group
UBS
+$10.2M
4
DIS icon
Walt Disney
DIS
+$9.97M
5
CBL
CBL Properties
CBL
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 2.56%
2 Technology 1.89%
3 Consumer Discretionary 0.9%
4 Communication Services 0.87%
5 Industrials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENV
626
PUT
DELISTED
ENVESTNET, INC.
ENV
$1.19M 0.02%
+20,000
New +$1.16M
LMB icon
627
CALL
Limbach Holdings
LMB
$866M
$1.17M 0.02%
+47,500
New +$955K
KURA icon
628
Kura Oncology
KURA
$806M
$1.17M 0.02%
+111,023
New +$1.31M
ITRI icon
629
Itron
ITRI
$4.44B
$1.15M 0.02%
16,000
+11,000
+220% +$696K
DSP icon
630
PUT
Viant Technology
DSP
$244M
$1.15M 0.02%
250,000
DBI icon
631
CALL
Designer Brands
DBI
$323M
$1.14M 0.02%
+113,000
New +$933K
CCI icon
632
Crown Castle
CCI
$33.8B
$1.14M 0.02%
10,000
-3,000
-23% -$357K
NTNX icon
633
Nutanix
NTNX
$16.3B
$1.12M 0.02%
+40,000
New +$1.06M
KKR icon
634
CALL
KKR & Co
KKR
$92.7B
$1.12M 0.02%
20,000
AVDL
635
DELISTED
Avadel Pharmaceuticals
AVDL
$1.11M 0.02%
67,193
-48,311
-42% -$628K
KZR
636
CALL
DELISTED
Kezar Life Sciences
KZR
$1.1M 0.02%
45,000
KZR
637
PUT
DELISTED
Kezar Life Sciences
KZR
$1.1M 0.02%
45,000
VIRT icon
638
Virtu Financial
VIRT
$5.08B
$1.09M 0.02%
+64,068
New +$1.17M
SPCE icon
639
PUT
Virgin Galactic
SPCE
$357M
$1.09M 0.02%
+14,095
New +$1.12M
DSGX icon
640
PUT
Descartes Systems
DSGX
$6.47B
$1.08M 0.02%
+13,500
New +$1.05M
ARWR icon
641
CALL
Arrowhead Research
ARWR
$12B
$1.07M 0.02%
30,000
ARWR icon
642
PUT
Arrowhead Research
ARWR
$12B
$1.07M 0.02%
30,000
CDNS icon
643
Cadence Design Systems
CDNS
$92.3B
$1.06M 0.02%
+4,500
New +$979K
GT icon
644
Goodyear
GT
$2.04B
$1.05M 0.02%
+76,600
New +$957K
CFG icon
645
CALL
Citizens Financial Group
CFG
$30.6B
$1.04M 0.02%
40,000
-60,000
-60% -$1.65M
BX icon
646
Blackstone
BX
$105B
$1.04M 0.02%
+11,200
New +$967K
NUGT icon
647
Direxion Daily Gold Miners Index Bull 2X ETF
NUGT
$869M
$1.04M 0.02%
+29,771
New +$1.25M
RGLD icon
648
CALL
Royal Gold
RGLD
$17B
$1.03M 0.02%
+9,000
New +$1.16M
ILMN icon
649
Illumina
ILMN
$30.9B
$1.03M 0.02%
5,654
+2,570
+83% +$520K
DBRG icon
650
CALL
DigitalBridge
DBRG
$2.93B
$1.03M 0.02%
70,000
-37,500
-35% -$460K

Similar funds

Caption Management's Q2 2023 Portfolio in Review

As of Q2 2023, Caption Management held 1,507 positions worth $5.65B, up 9.1% from $5.18B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Caption Management deployed $283M of net new capital in Q2 2023, opening 476 new positions and adding to 192 existing holdings. Its largest new stake was Lockheed Martin: 31,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 2.6% of assets, up from 2% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sabre, an estimated $12.5M trimmed.

  • Caption Management's largest Q2 2023 buy was Lockheed Martin: 31,000 shares worth $14.3M.
  • Caption Management added most to State Street SPDR S&P Biotech ETF in Q2 2023, an estimated $11M increase.
  • Caption Management's biggest Q2 2023 reduction was Sabre, cutting an estimated $12.5M.
  • Caption Management fully exited KraneShares CSI China Internet ETF in Q2 2023, selling an estimated $16.7M.
  • Caption Management's ten largest holdings make up 18% of its $5.65B portfolio in Q2 2023.
  • Caption Management opened 476 new positions and closed 448 in Q2 2023.
  • Caption Management's portfolio value rose 9.1% quarter-over-quarter to $5.65B.

Based on Caption Management's 13F filing for Q2 2023, filed 14 Aug 2023.